Dulaglutide

Dulaglutide is a long-acting GLP-1 receptor agonist developed by Eli Lilly, consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. This fusion protein design dramatically increases the molecular weight and reduces renal clearance, resulting in a half-life of approximately 5 days and enabling once-weekly dosing. The GLP-1 component is modified to resist DPP-4 degradation, and the Fc fragment is engineered to minimize immune effector functions.

Approved by the FDA in 2014 and marketed as Trulicity, dulaglutide rapidly became one of the most prescribed GLP-1 receptor agonists globally, in large part due to its user-friendly single-dose autoinjector pen that does not require visible needle handling. This design innovation addressed a major barrier to injectable therapy adoption among patients with type 2 diabetes.

The REWIND cardiovascular outcomes trial was a milestone for dulaglutide, demonstrating a 12% reduction in major adverse cardiovascular events (MACE) compared to placebo in a broad population of type 2 diabetes patients, including those without established cardiovascular disease. This was notable because most cardiovascular outcome trials for diabetes drugs had enrolled primarily patients with existing cardiovascular disease or high cardiovascular risk. The REWIND results expanded the evidence base for cardiovascular benefit to a broader, more primary prevention-oriented population.

In terms of glycemic efficacy, dulaglutide reduces HbA1c by approximately 1.0-1.5% depending on the dose and comparator. Weight loss is moderate, averaging 2-5 kg, which is less than observed with semaglutide but clinically meaningful. Higher doses (3.0 mg and 4.5 mg) approved more recently provide additional glycemic and weight benefits for patients requiring more intensive therapy.